Abiopharma

🔍 Lo Andrew (Director)

Company: BridgeBio Pharma, Inc. (BBIO)

Report Date: 2026-06-22

Detailed Transactions and Holdings:

• Acquired 3,990 shares of Common Stock (Direct)
  Date: 2026-06-22 | Code: A | equity_swap_involved: 0 | shares_owned_after: 18,079.00 | transaction_form_type: 4 | Footnotes: F1, F2
• Holds 0 shares of Common Stock (Direct)
  Date: 2026-06-22 | Code: H | nature_of_ownership: By Andrew W. Lo and Nancy N. Lo JTWROS | shares_owned_after: 50,583.00
• Acquired 5,277 shares of Stock Option (Right to Buy) at $68.92 per share (Derivative)
  Date: 2026-06-22 | Code: A | Expires: 2036-06-21 | equity_swap_involved: 0 | shares_owned_after: 5,277.00 | transaction_form_type: 4 | Footnotes: F3

Footnotes:

• F1: Grant of restricted stock units ("RSUs") under the Issuer's 2021 Amended and Restated BridgeBio Pharma, Inc. Stock Option and Incentive Plan. The RSUs vest in full on June 22, 2027, subject to the Reporting Person's continued service on the Issuer's board of directors through the vesting date.
• F2: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.
• F3: The shares underlying the stock option vest in full on June 22, 2027, subject to the Reporting Person's continued service on the Issuer's board of directors through the vesting date.